Your browser doesn't support javascript.
loading
Dual acting oximes designed for therapeutic decontamination of reactive organophosphates via catalytic inactivation and acetylcholinesterase reactivation.
Cannon, Jayme; Tang, Shengzhuang; Yang, Kelly; Harrison, Racquel; Choi, Seok Ki.
Afiliación
  • Cannon J; Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan Medical School Ann Arbor Michigan 48109 USA skchoi@umich.edu.
  • Tang S; Department of Internal Medicine, University of Michigan Medical School Ann Arbor Michigan 48109 USA.
  • Yang K; Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan Medical School Ann Arbor Michigan 48109 USA skchoi@umich.edu.
  • Harrison R; Department of Internal Medicine, University of Michigan Medical School Ann Arbor Michigan 48109 USA.
  • Choi SK; Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan Medical School Ann Arbor Michigan 48109 USA skchoi@umich.edu.
RSC Med Chem ; 12(9): 1592-1603, 2021 Sep 23.
Article en En | MEDLINE | ID: mdl-34671741
ABSTRACT
A conventional approach in the therapeutic decontamination of reactive organophosphate (OP) relies on chemical OP degradation by oxime compounds. However, their efficacy is limited due to their lack of activity in the reactivation of acetylcholinesterase (AChE), the primary target of OP. Here, we describe a set of α-nucleophile oxime derivatives which are newly identified for such dual modes of action. Thus, we prepared a 9-member oxime library, each composed of an OP-reactive oxime core linked to an amine-terminated scaffold, which varied through an N-alkyl functionalization. This library was screened by enzyme assays performed with human and electric eel subtypes of OP-inactivated AChE, which led to identifying three oxime leads that displayed significant enhancements in reactivation activity comparable to 2-PAM. They were able to reactivate both enzymes inactivated by three OP types including paraoxon, chlorpyrifos and malaoxon, suggesting their broad spectrum of OP susceptibility. All compounds in the library were able to retain catalytic reactivity in paraoxon inactivation by rates increased up to 5 or 8-fold relative to diacetylmonoxime (DAM) under controlled conditions at pH (8.0, 10.5) and temperature (17, 37 °C). Finally, selected lead compounds displayed superb efficacy in paraoxon decontamination on porcine skin in vitro. In summary, we addressed an unmet need in therapeutic OP decontamination by designing and validating a series of congeneric oximes that display dual modes of action.